1. The study showed a statistically significant gain (77%) in the treated eye (with RPE cells) over the control eye of the same animal. ， However, both the treated eye and the control eye were approximately 10 times more active (response to ERG) compared to non-treated (normally dystrophic) control animal.
2. The RPE and NSC cells were effective in preserving the thickness of the outer nuclei layer of the retina.
3. A contra lateral effect was observed between the test and control eyes. As a result, both eyes exhibited significant improvement。 It is believed that the positive outcome in the control eye was achieved through the systemic release of cytokines; growth and other important factors; peptides; and, molecules from stem cells transplanted into the treated eye. This phenomenon is referred to by Stemedica as “The Factor Release Effect” and branded by the company as StemedicaFRE™。 These factors, circulating in the blood flow, effect and mobilize endogenous stem cells. StemedicaStemedica believes improvement in the contra lateral eye is a 'Factor Release Effect' rather than a Sympathetic Ophthalmic effect which is very rare. Stemedica。 Stemedica discovered the presence of these endogenous RPE stem cells in adult retinas several years ago. This original research demonstrated that these RPE stem cells acquired embryonic markers (Nanog and Oct-4) in adult humans.
